The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Japan's Suga urges citizens to have a quiet and distanced New Year

Fri, 25th Dec 2020 04:37

(Updates with reports on first cases of mutated coronavirus)

By Kiyoshi Takenaka and Tetsushi Kajimoto

TOKYO, Dec 25 (Reuters) - Japanese Prime Minister Yoshihide
Suga urged the nation on Friday to spend a quiet New Year period
without the usual social gatherings to prevent the spread of
COVID-19, which has been breaking infection records almost on a
daily basis.

Suga also announced a package of $2.6 billion for hospitals
treating COVID-19 patients which have come under strain due to
the rapid rise in cases across the northern island of Hokkaido
as well as large cities like Tokyo and Osaka.

"I want you to spend a quiet New Year," the premier told a
news conference in Tokyo with the government's leading
coronavirus expert Shigeru Omi.

"The infections aren't coming down and if we keep going like
this, we won't be able to avoid further spread of the virus."

The country confirmed its first cases of the new, faster-
spreading variant of the virus, in two citizens who had arrived
from the United Kingdom, domestic media reported late on Friday.

Japan has banned entry from United Kingdom, with the
exception of returning Japanese nationals and those with
residence permits.

Japan does not celebrate Christmas, but the New Year period
is an extended national holiday, with many people usually
travelling back to their hometowns and spending time with family
and friends.

Omi warned that it was critical that "all citizens move in
the same direction," to get a grip on the health crisis.

"If we don't bring infections down now, once they surge
again after the New Year period it won't be easy to change the
downward trend," he said. "It would take time, and would
probably be impossible to control over a period of weeks," he
said.

Omi said shared meals were a major cause of infections and
called on people to refrain from holding large gatherings and to
limit meals to four people one regularly ate with, or fewer.

While Japan has avoided the huge infection numbers seen in
other parts of the world, the number of new daily cases
surpassed 3,000 for the first time this month. Tokyo reported
884 infections on Friday, near Thursday's record 888.

HOSPITALS, VACCINES

Underscoring the strain on the hospitals, five national
groups of doctors and other medical workers made an emergency
request to Suga on Friday, asking for strong anti-pandemic
measures and support for the medical sector.

With hospitals equipped for treating COVID-19 filling up,
other hospitals are being forced to accept patients with the
disease, according to Tsuyoshi Masuda, president of the Japan
Federation of Democratic Medical Institutions.

"These small and medium-sized hospitals, which have been
supporting medical services in their respective regions, are
facing a crisis that is threatening their survival," Masuda told
reporters at a separate news conference on Friday.

He also warned that the risk of in-hospital infections was
high at institutions not specialized in dealing with infectious
diseases.

Japan, with a population of 126 million, has struck deals
to buy 290 million vaccine doses from Pfizer Inc,
AstraZeneca Plc and Moderna Inc, or enough for
145 million people.

A health ministry panel said that people aged 65 or older
should get priority for vaccination against COVID-19, as well as
frontline healthcare workers and people with underlying medical
conditions.

It specified chronic heart disease, chronic respiratory
disease and chronic kidney disease, among others, as underlying
conditions that should determine priority.

The panel's recommendations would mean 36 million elderly
people and 8.2 million people with medical conditions would be
the first to receive shots.
(Reporting by Kiyoshi Takenaka, Ju-min Park, Testsushi Kajimoto
and Antoni Slodkowski; Editing by Shri Navaratnam, Edmund
Klamann and William Mallard)

More News
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.